Latest news with #TUS
Irish Examiner
12 hours ago
- Business
- Irish Examiner
Ballymore chief Sean Mulryan outlines plan to transform Athlone into green '15-minute city'
The founder of property firm Ballymore Sean Mulryan has proposed a plan to develop Athlone into a green '15-minute city' with a population of 100,000 in the next 15 years. Mr Mulryan has formed a steering group to look into the plan, which would see the TUS Athlone campus cater for up to 25,000 students as a centre of excellence in green technology and to construct 20,000 zero carbon homes in its first phases. It envisions road networks tailored for electric driverless buses, with 90% of Athlone's energy resources coming from renewable sources. "Our vision could drive genuine balanced distribution of the impending population growth in Ireland and offer a blueprint for sustainable, education-led, employment-driven, and environmentally focused urban development nationwide," said the Ballymore chair and chief executive, who is from Roscommon. 'We are sharing that vision now with wider Irish society, and we will do all we can to help it become a reality. But this plan needs to be driven from the top by government – by this administration and by the successor governments that take office in the years ahead – if it is to come to pass.' The new steering group for the plan sees Mr Mulryan joined by former chair of the Revenue Commissioners and chair of the governing body of Technological University of the Shannon, Josephine Feehily; Goldman Sachs private equity co-head and chair Adrian Jones, CAlchelyst chief Joan Kehoe, former DCU president Prof. Brian MacCraith,Iirhs Rail chief Jim Meade, and Ballymore deputy managing director Linda Mulryan-Condron, who is Mr Mulryan's daughter. Ballymore Group was established in 1982 by Mr Mulryan and has built 35,000 houses across Ireland, the UK, and Europe.
Hamilton Spectator
12-06-2025
- Business
- Hamilton Spectator
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) in an oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine, and an investigator in the TUSCANY study, reported safety and efficacy data from the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet. Dr. Mannis also noted three patients were rapidly enrolled on the third dose cohort of 120 mg TUS in the TUS+VEN+AZA triplet, and that no DLTs have been observed to date. The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Key findings: 'The TUSCANY triplet trial is well under way, and we are observing exciting activity with the addition of TUS to the VEN+AZA standard treatment,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. 'The data presented today reveal complete responses across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. TUS appears to have tremendous opportunity in the largest markets and the most challenging of AML cases.' Abstracts are available on the EHA2025 website here . The presentation is available on the Aptose website here . TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS, is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on ( here ). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit . Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@
Yahoo
12-06-2025
- Business
- Yahoo
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3-wildtype, safely achieved complete remissions and MRD negativity Ten AML patients dosed across 40 mg, 80 mg, and 120 mg TUS with TUS+VEN+AZA triplet SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) in an oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine, and an investigator in the TUSCANY study, reported safety and efficacy data from the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet. Dr. Mannis also noted three patients were rapidly enrolled on the third dose cohort of 120 mg TUS in the TUS+VEN+AZA triplet, and that no DLTs have been observed to date. The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Key findings: To date, ten newly diagnosed AML patients have received the TUS+VEN+AZA combination: Four received the 40 mg dose of TUS, three received the 80 mg dose of TUS, and three received the 120 mg dose of TUS At the initial dose of 40 mg TUS (n=4), with patients on longest duration of drug: Three subjects achieved CRs and were MRD-negative, including Patient with FLT3-ITD Patient with FLT3-WT Patient with TP53/CK At the 80 mg TUS dose level (n=3): All three patients (100%) already achieved composite complete remissions (CR and CRi) A TP53-mutated/CK AML patient achieved an early CRi Too early in treatment for final MRD assessment At the 120 mg TUS dose level (n=3): All three patients at the 120 mg TUS dose level remain on therapy Too early in treatment for formal response and MRD assessments Regardless of mutation status, TUS is active in newly diagnosed AML patients MRD-negative responses achieved across diverse genetic populations, including adverseTP53 mutations and CK Responses continue to evolve, and the triplet continues to be well tolerated with no DLTs TUS can be administered safely with standard-of-care dosing of VEN/AZA TUS PK properties not altered by VEN, AZA, antifungals or food No prolonged myelosuppression in Cycle 1 in the absence of AML No treatment-related deaths; all 10 subjects treated to date remain alive No treatment related QTc prolongation, CPK elevations, differentiation syndrome or non-hematologic SAEs 'The TUSCANY triplet trial is well under way, and we are observing exciting activity with the addition of TUS to the VEN+AZA standard treatment,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. 'The data presented today reveal complete responses across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. TUS appears to have tremendous opportunity in the largest markets and the most challenging of AML cases.' Abstracts are available on the EHA2025 website here. The presentation is available on the Aptose website here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS, is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@
Irish Times
10-06-2025
- Sport
- Irish Times
Leaving Cert student diary: ‘Biology isn't my strongest subject - but that was a lovely paper'
Do as much as possible in as little time as I can: that's been my motto for the past few weeks. I really pulled the socks up to get these exams over the line. So far, the exams have been good. I enjoyed the first English paper, though the second was trickier. Same with maths: a good paper one followed by a more difficult paper two. Irish was good, and I liked the essay titles which were broad and easy to expand on, although I found the listening comprehension more challenging than previous years. And biology, not my strongest subject, was such a lovely paper today, and definitely the most accessible in years. READ MORE I hope to study athletic and rehabilitation at TUS (Technological University of the Shannon), and this degree would allow me to move into a masters in physiotherapy. I've considered studying abroad, as the Netherlands offers a similar course and it would be delivered through English. But I think I'd prefer to stay here – I'm from the area, TUS is a good university, and I could keep up my part-time job in the local Dunnes Stores. I love sports and I play for the Garrycastle GAA club, so I could keep that up if I stay local. Of course, the cost of living away from home is huge, and accommodation is so hard to find, so being at home would be so much more affordable. I'm doing all higher-level subjects, except for maths. I'm already at a disadvantage. At the start of fifth year, I did higher-level maths because I wanted the chance to get those 25 bonus points. But I quickly realised that I would have to neglect my other subjects, especially the ones that I'm strong in. It wasn't an easy decision to automatically drop to ordinary level and be 25 points down – just because I have strengths other than maths. I ultimately decided it made more sense to focus on the subjects I actually liked, but I know that so many do higher-level maths, struggle with it and fall behind in their other subjects. I just don't understand who this system serves. Still to come: Spanish, agricultural science and construction studies. For those last two, I've already done a significant chunk through project work. Nearly there. I'm aiming for as high as I can get – then it's time to put the feet up, relax and go on our Leaving Cert Albufeira trip. – Killian Keegan is a Leaving Cert student at Athlone Community College
Irish Times
06-06-2025
- Health
- Irish Times
Leaving Cert student diary: ‘I'm proof there's an alternative to incredibly stressful exams'
I'm only young, so it's fair to say I don't follow the ins and outs of education policy. But I do hear, from my friends and on the news, about how incredibly stressful the Leaving Cert is and how it needs to be reformed. I and the other 4,512 students sitting the Leaving Cert Applied [LCA] are living proof that there is a different way. The LCA means students like me, who prefer practical and vocational approaches, are not left behind. I know Ireland is trailing other European countries in terms of offering this vocational option, although the numbers sitting the LCA are growing every year. The LCA offers entry routes to college too. I am hoping to get into a post-Leaving Cert course: nursing studies at Moate ETB [education and training board]. It gives us a foundation in nursing, includes practical experience and a work placement, and is also linked to a general nursing course at TUS [Technological University of the Shannon]. READ MORE Over the past few years, I decided to learn sign language. I'm not doing it as an examined subject, but I felt that it would be a really useful skill for a nurse to have, as it means I can communicate with more people. I'm not fluent, but I can hold a basic conversation and I hope to improve. As for the exams? It's a case of so far, so good. I appreciated the layout of the papers and they haven't been as difficult as I expected. English and communications was probably my best so far, as a lot of the topics I studied appeared. Hotel catering and tourism, however, was probably the most challenging, although still achievable. In this subject, we learn about restaurants, tourist sites and we work on menus for parties and for people with food allergies and intolerances, such as coeliac disease. LCA students have already done a lot of projects and continuous assessment throughout the year, so that relieves the pressure of a single, high-stakes exam. [ Leaving Cert and Junior Cycle: Record 140,000 to sit State exams Opens in new window ] I can't believe the end is in sight, as I finish up on Tuesday with an exam on construction and graphics. I'll miss my classmates in school. There's only been eight of us in the entire LCA programme, so we became tight-knit. I currently commute for over an hour every day to and from school. This is because we moved a few years ago but I wanted to stay in the same school. I wish there was better public transport, particularly for rural areas, as there's currently only two buses a day. It's safe to say that I won't miss this commute. – Amy Cox is a Leaving Cert Applied student at Athlone Community College
